Nephropathy News and Research

RSS

Nephropathy is a broad medical term used to denote disease or damage of the kidney, which can eventually result in kidney failure. The primary and most obvious functions of the kidney are to excrete any waste products and to regulate the water and acid-base balance of the body – therefore loss of kidney function is a potentially fatal condition.

Affymax, Takeda to regulate peginesatide drug for treating anemia in CRF patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited , today announced that following pre-New Drug Application (NDA) discussions with the U.S. Food and Drug Administration (FDA), the companies will move forward with their regulatory strategy for the investigational drug, peginesatide, for the treatment of anemia in chronic renal failure (CRF) patients on dialysis in the United States.

29 Nov 2010

Mercury from dental fillings exceeds Reference Exposure Level: Report

A new risk assessment report submitted by the International Academy of Oral Medicine and Toxicology this month to the U.S. Food and Drug Administration (FDA) warns that mercury from dental fillings is estimated to cause 67.2 million Americans to exceed the Reference Exposure Level (REL) of 0.3 ug/m3 established by the U.S. Environmental Protection Agency (U.S. EPA) in 1995.

25 Nov 2010

DaVita announces emergency preparedness information for dialysis patients during winter season

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD) and end stage renal disease (ESRD), announced today important emergency preparedness information for dialysis patients during the upcoming winter season.

23 Nov 2010

Medicare making changes to acknowledge telemedicine's growing use

American Medical News: Through teleconferencing technology, doctors are able to treat patients who live far away without access to a specialist. "Nationwide, telemedicine increasingly is being used to bridge gaps in access to care in rural and other medically underserved communities that have a hard time recruiting physicians.

23 Nov 2010

Dangers of excess fructose

More and more people have become aware of the dangers of excessive fructose in diet. A new review on fructose in an upcoming issue of the Journal of the American Society of Nephrology (JASN) indicates just how dangerous this simple sugar may be.

23 Nov 2010

Medtronic enters merger agreement to acquire Ardian

Medtronic, Inc. and privately-held Ardian, Inc. announced today that they have entered into a merger agreement whereby Medtronic will acquire Ardian.

22 Nov 2010

DaVita announces meal planning tool for dialysis patients

DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease (ESRD) and chronic kidney disease (CKD), offers patients with very restricted diets an easy to use meal planning tool and recipes for their favorite Thanksgiving dinners at DaVita.com.

22 Nov 2010

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.

22 Nov 2010

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

On November 20 at the American Society of Nephrology 43rd Annual Meeting, Columbia University Assistant Professor of Clinical Medicine Andrew Bomback, MD, presented results from a patient case series assessing the potential therapeutic value of H.P. Acthar Gel (repository corticotropin injection) as a treatment for patients with nephrotic syndrome, a kidney disorder characterized by excessive loss of urinary protein.

22 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Research shows association between childhood CKD and maternal diabetes, obesity

Children with Chronic Kidney Disease (CKD) are more likely to have mothers who were obese or had diabetes during pregnancy, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition, by Christine W. Hsu, MD (University of Washington, Seattle) and colleagues.

22 Nov 2010

Racial and socioeconomic disparities exist in kidney transplantation

Research shows that people with low incomes are more likely to develop kidney failure and less likely to receive a living donor kidney transplant than people of other socioeconomic classes.

22 Nov 2010

Study finds common gene variant in African Americans increases risk of kidney disease

In African Americans with kidney disease related to hypertension (high blood pressure), a common gene variant is associated with a sharply increased risk of progressive kidney disease, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition. End Stage Renal Disease (ESRD) associated with hypertension occurs in the African American population at a rate 13.1 times greater than that of their white counterparts.

22 Nov 2010

SHARP study shows cholesterol-lowering effective for patients with kidney disease

Around a quarter of all heart attacks, strokes, and operations to open blocked arteries could be avoided in people with chronic kidney disease by using the combination of ezetimibe and simvastatin to lower blood cholesterol levels. That's the conclusion from the world's largest ever randomized trial in kidney disease.

22 Nov 2010

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug.

22 Nov 2010

Inexpensive intervention helps patients with hypertension-associated kidney disease

In patients with kidney disease, the Western diet produces an acidic environment in the body that has numerous negative effects and worsens with age as kidney function declines.

21 Nov 2010

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.

21 Nov 2010

Presence of albumin in urine predicts cognitive decline: Study

A new study has found that low amounts of albumin in the urine, at levels not traditionally considered clinically significant, strongly predict faster cognitive decline in older women.

21 Nov 2010

Scientologists target Aborigines with “drug bombs”

The Northern Territory (NT) Health Department of Australia last Saturday warned the Church of Scientology that its drug detoxification therapy, being promoted to Aborigines in Australia by the church was dangerous for people with kidney problems.

21 Nov 2010

Nephrologist’s care reduces ESRD development during first year of dialysis: Study

Among kidney disease patients, earlier care from a nephrologist is associated with a decreased likelihood of developing end-stage renal disease and a lower risk of death during the first year of dialysis, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition.

20 Nov 2010

Nephropathy News and Research

Further Reading

Affymax, Takeda to regulate peginesatide drug for treating anemia in CRF patients

Mercury from dental fillings exceeds Reference Exposure Level: Report

DaVita announces emergency preparedness information for dialysis patients during winter season

Medicare making changes to acknowledge telemedicine's growing use

Dangers of excess fructose

Medtronic enters merger agreement to acquire Ardian

DaVita announces meal planning tool for dialysis patients

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

VYTORIN reduces major vascular events in patients with chronic kidney disease

Research shows association between childhood CKD and maternal diabetes, obesity

Racial and socioeconomic disparities exist in kidney transplantation

Study finds common gene variant in African Americans increases risk of kidney disease

SHARP study shows cholesterol-lowering effective for patients with kidney disease

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Inexpensive intervention helps patients with hypertension-associated kidney disease

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Presence of albumin in urine predicts cognitive decline: Study

Scientologists target Aborigines with “drug bombs”

Nephrologist’s care reduces ESRD development during first year of dialysis: Study

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News